ストックスクリーナーアプリを入手
1.03
0.00%
0.00
Clearmind Medicine Inc (CMND) 最新ニュース
Clearmind launches data system for alcohol addiction trial - Investing.com
Clearmind Implements EDC System To Streamline Phase I/II Trial For Alcohol Use Disorder Drug - Nasdaq
Clearmind Medicine launches EDC system to support Phase I/II trial - TipRanks
Clearmind launches data system for alcohol addiction trial By Investing.com - Investing.com Australia
Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment - The Manila Times
Psychedelic: Exclusive talk with biotech company Clearmind Medicine - Yahoo Finance
Clearmind’s AUD drug candidate arrives in the U.S. for trials By Investing.com - Investing.com South Africa
Clearmind Medicine Moves Closer to CMND-100 Trial After Alcohol Use Disorder Drug Candidate Arrives in US - MarketScreener
Clearmind’s AUD drug candidate arrives in the U.S. for trials - Investing.com
Clearmind Medicine's FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones - The Manila Times
Clearmind Medicine Inc. Announces Arrival of CMND-100 in the U.S. Ahead of Phase I/IIa Trial for Alcohol Use Disorder - Nasdaq
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones - TradingView
Clearmind and Polyrizon partner on nasal drug delivery By Investing.com - Investing.com South Africa
Clearmind Medicine To Develop Novel Intranasal Formulation With Polyrizon - Nasdaq
Clearmind and Polyrizon partner on nasal drug delivery - Investing.com
Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination - The Manila Times
Clearmind begins phase I/IIa trial for AUD treatment - Investing.com Australia
Clearmind Medicine Advances CMND-100 To Clinical Trials For Alcohol Use Disorder - Nasdaq
Clearmind Medicine Initiates First Clinical Trial Of CMND-100 For Alcohol Use Disorder Treatment - Nasdaq
Clearmind begins phase I/IIa trial for AUD treatment By Investing.com - Investing.com South Africa
Clearmind Begins Human Trials for Potential Psychedelic Treatment for Alcohol Abuse Patients - Marketscreener.com
Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients - The Manila Times
Clearmind Medicine Inc. Initiates Phase I/IIa Clinical Trial for CMND-100 in Alcohol Use Disorder Patients - Nasdaq
Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in ... - The Bakersfield Californian
Clearmind Medicine (CMND) versus Its Peers Head to Head Contrast - Defense World
Clearmind secures South Korean patent for addiction therapy By Investing.com - Investing.com Australia
Bulls Turn to Pennies STSS, ADTX, CSDX, SPRC, CBDW, YGTFF During Market Uncertainty – Small-Cap Stocks Poised for Big Moves - Financial Content
SciSparc-Clearmind Collaboration Leads to Publication of - GlobeNewswire
SciSparc Shares Are Soaring Monday: What's Going On? - Benzinga
Scisparc, Clearmind apply for patent in South Korea for its co-developed treatment to overcome cocaine addiction - Marketscreener.com
Clearmind secures South Korean patent for addiction therapy - Investing.com
SciSparc announces publication of patent via Clearmind collaboration - TipRanks
SciSparc Ltd. and Clearmind Medicine Inc. Announce Patent Application for Combination Treatment of Cocaine Addiction - Nasdaq
SciSparc Advances Cocaine Treatment Patent Following Successful Preclinical Data - StockTitan
Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea - The Manila Times
Clearmind Medicine Announces Publication Of Patent For Cocaine Addiction Psychedelic Combination Treatment In South Korea - MENAFN.COM
Clearmind Medicine Inc. Announces Patent Publication for Innovative Combination Therapy Targeting Cocaine Addiction - Nasdaq
SciSparc Ltd. announced that it expects to receive $2 million in funding from Yorkville Advisors Global LP - Marketscreener.com
Obesity Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Head-To-Head Comparison: Clearmind Medicine (CMND) versus The Competition - Defense World
Clearmind Medicine (NASDAQ:CMND) Stock Quotes, Forecast and News Summary - Benzinga
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico - GlobeNewswire
SciSparc and Clearmind’s Patent Publication Marks Progress in Binge Behavior Treatment - TipRanks
Clearmind Medicine Secures Patent For Psychedelic Combination Therapy In Mexico - Nasdaq
SciSparc Ltd.-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico - Marketscreener.com
SciSparc Ltd. and Clearmind Medicine Inc. Collaborate on Patent Application for Innovative Combination Therapy to Address Binge Behaviors - Nasdaq
Game-Changing Addiction Treatment Patent: SciSparc-Clearmind's MDMA Breakthrough Expands Global Reach - StockTitan
Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico - The Manila Times
Clearmind Medicine Inc. Announces Patent Publication for Innovative Combination Therapy Targeting Binge Behavior - Nasdaq
Novel Psychedelic-Based Therapy Gets Patent Green Light: Targets Multiple Addictions - StockTitan
EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds - MSN
SciSparc Ltd. Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing - Marketscreener.com
Clearmind Medicine (NASDAQ:CMND) Trading Up 6.3% – Still a Buy? - Defense World
SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com
Clearmind Medicine Announces Shareholders Meeting Results - The Manila Times
Scisparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment - Marketscreener.com
SciSparc and Clearmind Medicine Advance with European Patent Application for Psychedelic Binge Behavior Treatment - TipRanks
3.01%
大文字化:
|
ボリューム (24 時間):